Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Schering Says Image Quality Hobbled Vytorin Study
Link ID 2129
Title Schering Says Image Quality Hobbled Vytorin Study
Url http://www.medscape.com/viewarticle/568242?src=rss
Description The chief executive of Schering-Plough Corp on Thursday said poor quality of ultrasound images hobbled a closely watched trial of its Vytorin cholesterol fighter, and stressed that the controversial study involved a "narrow population" of patients. Reuters Health Information
Category Articles > Business of Medicine
Keywords
Date Jan 5, 2008
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Business of Medicine
1. U.S. Hospital Companies Still Face Major Challenge
  The rally in U.S. hospital stocks, prompted by a major earnings beat by Universal Health Services, may be overdone as unpaid medical bills and slowing patient admissions dog the sector. Reuters Health Information
Category:   Articles > Business of Medicine


2. Tarenflurbil Fails to Meet Primary End Point in Phase 3; End of the Road for Development
  In a brief statement, Myriad Genetics reports that tarenflurbil failed to have a significant effect in mild AD patients in a phase 3 trial and announced that it will not continue development of the compound. Medscape Medical News
Category:   Articles > Business of Medicine


3. To "Glow" Where No One Has Gone Before: The Risk for Radiation to Space Exploration
  What we are learning about the effects of radiation in space has implications on Earth. Medscape Internal Medicine
Category:   Articles > Business of Medicine


4. FDA Approvals: Cymbalta
  The FDA has approved a new indication for duloxetine HCl delayed-release capsules (Cymbalta). Medscape Medical News
Category:   Articles > Business of Medicine


5. FDA Finds Olanzapine Injectable "Not Approvable" for Schizophrenia
  Eli Lilly announced the FDA has found their injectable form of olanzapine "not approvable" because of ongoing concern about excessive sedation seen in some patients after injection. Medscape Medical News
Category:   Articles > Business of Medicine




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS